Cargando…
Antibody-drug conjugates: beyond current approvals and potential future strategies
The recent approvals for antibody-drug conjugates (ADCs) in multiple malignancies in recent years have fuelled the ongoing development of this class of drugs. These novel agents combine the benefits of high specific targeting of oncogenic cell surface antigens with the additional cell kill from high...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Open Exploration
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400743/ https://www.ncbi.nlm.nih.gov/pubmed/36046842 http://dx.doi.org/10.37349/etat.2022.00082 |